Australia · Delayed Price · Currency is AUD Tryptamine Therapeutics Company Description
Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States.
The company’s lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness.
It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome.
The company was founded in 2019 and is based in Camberwell, Australia.
| Country | Australia |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Jason Carroll |
Contact Details
Address: 697 Burke Road Camberwell, Victoria 3124 Australia | |
| Phone | 61 3 9092 0475 |
| Website | tryptherapeutics.com |
Stock Details
| Ticker Symbol | TYP |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jason Alan Carroll | MD, Chief Executive Officer and Executive Director |
| Dr. James P. Gilligan MSIB, Ph.D. | President and Chief Scientific Officer |
| Christopher Leo Ntoumenopoulos | Executive Director |
| Hamish George B.Com., C.A. | Chief Financial Officer and Company Secretary |